Novavax Inc: The New Covid-19 Vaccine People are Waiting For
Novavax, Inc is generally a small vaccines development pharmaceuticals company in America. This late-stage biotechnical company was founded in 1998. The company is mainly creating an impactful influence on the global health and development sector by inventing several kinds of vaccines. It already has acquired an experience of decades in the disease preventive clinical trial field by its constant experimental nature.
Till now the company has invented multiple vaccines for disease like seasonal influenza, RSV, Ebola, MERS and SARS. Although the maximum vaccines of Novavax, Inc got rejected at trial phases, they still didn’t give up. They constantly experimented to innovate something impactful in the disease preventive treatment field.
The New Covid Vaccine by Novavax, Inc
Following the history, the company has now launched its latest vaccine for the ongoing life-threatening disease coronavirus. In June 2020 the company has first invented the NVX-CoV2373 which seems quite promising. By this means Novavax now took a part in the global race of corona vaccines invention. This treatment is a formulation of baculovirus and spike protein.
Has It Been Approved Yet?
The vaccine by Novavax is now passing through its last phase of clinical trial and the company is initially levelling as a dark horse. During the first trial, the vaccine has shown 89% of efficacy in the body of participants. Later, after one year, the efficacy level fell down and reached 50% to 60% approximately.
A study in the USA has claimed that this vaccine of Novavax, Inc comparatively works better on the patients on emergency stage.
In January 2021 it saw a successful development and passed the third stage of the clinical trial with an eighty-nine per cent efficiency gain. So the researchers are now again considering NVX-CoV2373 as a hopeful medication in terms of coronavirus prevention.